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Abstract
17a-hydroxylase/17, 20-lyase deficiency (17OHD) is an autosomal recessive disease causing congenital adrenal hyperplasia
and a rare cause of hypertension with hypokalemia. The CYP17A1 gene mutation leads to 17OHD and its clinical features.
We described an 18 y/o female with clinical features of 17a-hydroxylase/17, 20-lyase deficiency and characterized the
functional consequences of an intronic CYP17A1 mutation. The coding regions and flanking intronic bases of the CYP17A1
gene were amplified by PCR and sequenced. The patient is a compound heterozygote for the previously described p.R358X
and IVS1 +2T.C mutations. A first intron splice donor site mutation was re-created in minigene and full-length expression
vectors. Pre-mRNA splicing of the variant CYP17A1 intron was studied in transfected cells and in a transformed
lymphoblastoid cell line. When the full-length CYP17A1 gene and minigene containing the intronic mutation was expressed
in transfected cells, the majority (.90%) of mRNA transcripts were incorrectly spliced. Only the p.R358X transcript was
detected in the EBV-transformed lymphoblastoid cell line. The IVS1 +2T.C mutation abolished most 17a-hydroxylase/17,
20-lyase enzyme activity by aberrant mRNA splicing to an intronic pseudo-exon, causing a frame shift and early termination.
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Introduction
17a-hydroxylase deficiency (17OHD), a rare autosomal reces-
sive disease caused by CYP17A1 gene mutation, accounts for about
1% of all congenital adrenal hyperplasia and is characterized by
hypertension, hypokalemia, and sexual infantilism [1]. The
CYP17A1 enzyme catalyzes two different enzymatic reactions:
17a-hydroxylation of progesterone and pregnenolone and the
17,20 lyase reaction for the conversion of 17-hydroxypregneno-
lone to dehydroepiandrosterone (DHEA). Defects in these two
enzymatic reactions lead to decreased glucocorticoid and sex
steroid production with mineralocorticoid excess, primarily 11-
deoxycorticosterone and corticosterone, as well as 18-hydroxy-
deoxycorticosterone and 18-hydroxycorticosterone. Clinically,
patients present with lack of pubertal development, hypertension,
and hypokalemia with renal potassium wasting [2].
There are more than 70 inactivation mutations of CYP17A1
leading to 17OHD being reported, and six of them are intron
mutations [3–8]. Four intron mutations showed ‘‘exon skipping’’
to the next intron-exon boundary or to cryptic adjacent splice sites
by in vitro analysis using partial or full-length CYP17A1 gene,
whereas no functional studies were performed on the two first
intron mutations. In the present study, we describe a patient with a
first intron splice donor site mutation and characterize the
aberrant splicing in transfected cells and in lymphoblastoid cells
derived from the patient.
Materials and Methods
Ethics Statement
The study protocol was approved by the institutional review
board of the Kaohsiung Medical University Hospital (KMUH-
IRB-980005). Informed consents have been obtained in written
form from patient and her relatives and all clinical investigation
was conducted according to the principles expressed in the
Declaration of Helsinki. The patient and her relatives gave consent
for the publication of the clinical details.
Case Report
A Chinese female of non-consanguineous parents was evaluated
due to irregular menstruation, no breast development, and no
axillary and pubic hair at the age of fourteen. Ovarian failure and
hypogonadism was diagnosed, and she received estradiol and
progesterone treatment since then. Four years later, at the age of
18, she visited our facility for further evaluation. Chromosome
study showed normal 46,XX karyotype. Pelvic ultrasound showed
retarded uterus development (7.63 cm61.47 cm63.69 cm) and
bilateral ovaries (right: 2.33 cm60.91 cm62.45 cm and left:
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development. The bone age was significantly retarded at 13 years,
and her height was 170 cm (height-for-age z-score=+2.33). She
was referred to nephrology due to hypertension, hypokalemia, and
mild proteinuria. At initial visit, her blood pressure was 160/
100 mmHg, potassium level of 3.1 mEq/liter, urine protein/
creatinine ratio of 0.54 (mg/mg), and transtubular potassium
gradient (TTKG) of 10.49. Plasma renin, aldosterone, and other
biochemistry data are listed in Table 1. Mineralocorticoids and
glucocorticoids (Table 1) were measured by ultrapressure liquid
chromatography tandem mass spectrometry (UPLC-MS/MS)
according to the previously described method [9]. In brief,
aliquots of samples, calibrators and controls were extracted by
solid phase extraction (SPE) using Oasis MAX SPE system plates
(Waters, Milford, MA, USA). Deuterium labeled steroids were
used as internal standards. The UPLC-MS/MS system was used
in the multiples reaction monitoring mode (MRM) and steroids
were measured in the positive ion mode except aldosterone which
was measured in the negative mode. For each hormone two
different MRM transitions were monitored. The limit of
quantification was between 0.1 nmol/L for 17-hydroxyprogester-
one and 2 nmol/L for cortisol. The intra- and inter assay
coefficient of variations (%CV) for replicate quality controls for
different concentrations range between 2.4% and 9.7%. Total run
time for the assay was 5 min. Clinically, 17a-hydroxylase
deficiency was suspected. After 2 months of 10 mg prednisolone
daily, her blood pressure improved with disappearance of
hypokalemia and proteinuria.
DNA, RNA Isolation and Sequencing
Genomic DNA was extracted from peripheral blood leukocytes
of the patient, her mother, her brother, and a maternal uncle. The
eight exons and intron-exon boundaries of CYP17A1 gene were
amplified by PCR using primers and conditions described
previously [10]. PCR products were confirmed by electrophoresis
in 1.5% agarose gel and sequenced by ABI 3730XL DNA
Analyzer (Applied Biosystems, Foster City, CA). Total RNA was
collected from the patient’s peripheral blood leucocytes by the
standard Trizol method (Invitrogen, Carlsbad, CA). The reference
sequences of CYP17A1 gene and mRNA were NG_007955.1 and
NM_000102.3, respectively.
Minigene and Full-Length Gene Construction
The genomic CYP17A1 in pcDNA3 (Invitrogen, Carlsbad, CA)
vector was used as previously described [7]. A wild type CYP17A1
minigene, which spans exon 1 to exon 3, was made by cutting the
whole CYP17A1 vector with EcoRI and self-ligation of the
resulting plasmid. The IVS1 +2T.C minigene mutant was
created by QuikChange Mutagenesis kit (Stratagene, Cedar
Creek, Texas, USA) with primer pair 59-GCGGCCTCAAATGG-
CAAGTGGTGCCCATC-39 and 59- GATGGGCACCACTTG
CCATTTGAGGCCGC-39, while the full-length mutant was
made with 59-CTGGGCGGCCTCAAATGGCAAGTGGTGC-
CCATCTCCTCCC-39 using a single primer method [11], and
verified by partial sequencing.
Transient Transfection, RT-PCR, and Western Blot
HEK-293 cells and COS-7 cells were obtained from American
Type Culture Collection (Manassas, VA). Cells were transfected
with equal amount of plasmids containing the wild-type or
mutated CYP17A1 minigene by FuGENE6 (Roche, USA)
according to the manufacture’s protocol. Cells were harvested
24 h after transfection and total RNA or total protein was
extracted followed by RT-PCR and Western blot analysis [12].
The RNA samples were reverse transcribed with the M-MLV RT-
PCR kit (Promega, USA). Primers a-e used for PCR are: a, 59-
GCCACCATGTGGGAGCTCGTG-39;b ,5 9-TGGCTCTCTT-
GCTGCTTACC-39;c ,5 9-GTTGTTGGACGCGATGTCTA-
39;d ,5 9-GGGGACTAGGTCCACCAGGCT-39;e ,5 9-TGTGA-
TGCAGCGCCCACAGA39. The RT-PCR products were sepa-
rated on 1.5% agarose gels, purified, and directly sequenced or
subcloned by the TOPO TA Cloning Kit (Invitrogen, Carlsbad,
CA, USA) when needed. Lymphoblastoid cell lines (LCL) were
established by EBV-transformation of lymphocytes from the
patient as described [13]. Goat anti-CYP17A1 polyclonal IgG
(N-18, sc-46085, Santa Cruz Biotechnology) was used in the
Western blot analysis.
Results
Sequencing of the eight exons and intron-exon boundaries of
CYP17A1 gene showed compound heterozygous mutations at
position IVS1 +2T.C in intron 1 and p.R358X in exon 6.
Analysis of DNA from her mother and paternal uncle showed that
the p.R358X mutation derived from the father while mutation
IVS1 +2T.C was inherited from her mother (Fig. 1). The IVS1
+2T .C and R358X mutations both have been reported
previously [8], [14].
To analyze the effect of first intron donor site mutation on the
CYP17A1 mRNA splicing, CYP17A1 minigenes were constructed
(Fig. 2A) and transiently transfected into HEK-293 and COS-7
cells. The wild type minigene expressed only the expected 311 bp
mRNA product in both COS-7 and HEK-293 cells (Fig. 2B). In
contrast, the minigene construct containing the IVS1 +2T.C
mutation primarily yielded a ,400 bp RT-PCR product, plus a
trace of the 311 bp transcript (Fig. 2A). After TOPO cloning and
sequencing, a total of 4 different mRNA products, A to D, were
identified (Fig 2B). A 1983 bp fragment corresponding to the
genomic DNA sequence derived from either residual DNA or
unspliced pre-mRNA.
Table 1. Patient’s adrenal steroid metabolites.
Hormones Patient Reference ranges
ACTH, pg/ml (pmol/l) 272 (59.84) ,60 (13.2)
Estradiol, pg/ml (pmol/l) 10.9 (,40.3) 60–200 (222–740)
DHEA Sulphate, mg/dl (mmol/l) 3.7 (0.0987) 130–980 (3.47–26.13)
Progesterone*, ng/ml (nmol/l) 1.8 (5.72) 0.03–1.84 (0.095–5.85)
11-Deoxycorticosterone*, ng/ml
(nmol/l)
2.9 (8.75) 0.03–0.36 (0.09–1.09)
Corticosterone*, ng/ml (nmol/l) 71.9 (207.5) 0.28–4.59 (0.808–13.25)
Aldosterone, pg/ml (nmol/l) 205.2 (56.94) 40–310 (11.1–86.03)
17-OH progesterone*, ng/ml (nmol/l) ,0.03 (0.091) 0.14–0.79 (0.426–2.406)
11-Deoxycortisol*, ng/ml (nmol/l) ,0.03 (0.087) 0.03–2.2 (0.087–6.36)
Cortisol*, ng/ml (nmol/l) 14 (38.6) 50–249 (137.9–686.8)
Cortisone*, ng/ml (nmol/l) ,0.03 (0.083) 3.7–28.0 (10.26–77.68)
Androstenedione*, ng/dl (nmol/l) ,3 (104.9) 3–157 (0.105–5.49)
Testosterone*, ng/dl (nmol/l) ,5( ,0.1735) 3–49 (0.1041–1.7)
Renin, pg/ml (nmol/l) ,2.55 (60.4) 5.1–38.7 (120.9–917.2)
ACTH, Adrenocorticotropic hormone; DHEA, dehydroepiandrosterone.
SI units were given in parentheses. Asterisk (*) indicates analytes assayed by LC-
MS/MS.
doi:10.1371/journal.pone.0025492.t001
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revealed different splicing sites for each transcript. Variant A was
identical to the wild type sequence with length of 311 bp,
indicating a fraction of proper pre-mRNA splicing despite the
mutation. In variants B to D, pseudo-exons of various lengths were
created within the first intron using different cryptic splicing donor
and acceptor sites (Fig. 2C). A downstream stop codon was
generated in these three alternatively spliced mRNA forms, either
within the original intron region (variant C and D) or in the second
exon due to frame shifting (variant B). Immunoblots of protein
from cells expressing the mutant CYP17A1 gene contained reduced
amounts of CYP17A1 protein compared to cells expressing the
wild-type gene (Fig 2D).
While a single round of RT-PCR yield no visible bands or
irreproducible results from RNA isolated from patient’s peripheral
blood and LCL (data not shown), semi-nested PCRs performed on
RNA from the patient’s LCL gave a predominant ,300 bp-
amplicon using a primers in the first and second exons (primers b
and c, Fig 3A, lane 1). After TA cloning of the PCR products, two
out of twenty clones were ,400 bp amplicons, and sequencing
identified this fragment to be the same as the major form B
obtained from transfected cells. RT-PCR using primers in exons 1
and 3 or exons 1 and 6 (primers b and d or primers b and e)
yielded the expected amplicons of 644 and 1191 bp. Direct
sequencing of the 1191 bp fragment showed only the paternal
p.R358X sequence (Fig 3B), suggesting that most if not all full-
length CYP17A1 mRNA in the LCL derives from the p.R358X
allele.
Discussion
The CYP17A1 p.R358X mutation has been reported in one girl
of Korean descent with combined 17a-hydroxylase/17,20-lyase
deficiency, who presented with primary amenorrhea, sexual
infantilism, and hypertension [14]. Although p.R358Q caused
isolated 17,20-lyase deficiency [15], the p.R358X mutation
produces a premature stop codon and encodes a protein lacking
the heme moiety essential for catalytic activity. The IVS1 +2T.C
Figure 1. Pedigree analysis of CYP17A1 gene. The patient is found to be a compound heterozygous for mutations of CYP17A1. The first mutation
was identified as IVS1 +2T.C and the second mutation p.R358X (CGARTGA). The first intron mutation is originated from her mother and p.R358X
from her father, based on the analysis of her uncle’s genomic DNA. Proband’s brother is also heterozygous for the affected maternal allele.
doi:10.1371/journal.pone.0025492.g001
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clinical description and functional characterization [8]. We find
that over 90% of the pre-mRNA is aberrantly spliced,
eliminating most but not all enzymatic activity and explaining
the origin of low but detectable serum cortisol and breast
development in this severely affected patient. Presumably, non-
sense mediated degradation further reduced the abundance of
mRNA transcripts from both mutant alleles relative to wild-type
CYP17A1 (Figs 2 & 3). The suppression of aldosterone in
17OHD is variable [1], even within the same family [16].
Normal or even high aldosterone with suppressed renin has been
reported [4], [10], [16–18]. The factors leading to detectable
aldosterone in 17OHD are not known [19]. In contrast, 18-
hydroxydeoxycorticosterone and 18-hydroxycorticosterone are
often elevated in 17OHD [20], due to elevated precursor
synthesis and the weak 18-hydroxylase activity of CYP11B1 in
the zona fasciculata. Because 18-hydroxycorticosterone is the
immediate precursor to aldosterone, aldosterone production in
some 17OHD cases might reflect either synthesis driven by
precursor excess or cross-reactivity in the clinical assays.
Furthermore, hypertension is not caused by aldosterone excess
in 17OHD, thus the variability in hypertension is not caused by
variable aldosterone concentrations.
Ideally, direct demonstration of the functional consequences of
CYP17A1 intronic mutations requires analysis of either gonadal or
adrenal tissue to confirm the finding in model systems [5], [21].
Inconsistent RT-PCR analysis was found between RNA from
peripheral blood cell and tissue in other cases of 17OHD, which
might be due to the degradation of large hnRNA in the tissue [21].
This approach is problematic since many 17OHD patients do not
need surgical removal of their gonad and adrenal glands, except
for cryptorchid testes in patients with a 46,XY karyotype due to
potential malignancy. Alternatively, the use of heterologous
minigene expression studies, although somewhat artificial, usually
predicts cryptic splicing sites with high accuracy. Previous use of
full-length CYP17A1 gene expression demonstrated the feasibility
of simultaneous protein and RNA analysis to characterizing
intronic mutations [7].
Accurate pre-mRNA splicing is catalyzed by the spliceosome, a
large complex composed of five small nuclear ribonucleoproteins
(snRNPs), which recognizes conserved sequences at the exon-
intron boundaries and branch point sites [22]. The 59 splicing site
Figure 2. Heterologous expression and mRNA analysis using minigene and full-length CYP17A1 gene, wild-type and mutation IVS1
+2T.C. A) RT-PCR analysis shows only the correct 311 bp amplicon when wild-type CYP17A1 minigene or full-length gene is expressed in COS-7 or
HEK293 cells. In contrast, the IVS1 +2T.C mutant CYP17A1 gene affords primarily a ,400 bp amplicon, best demonstrated in COS-7 cells, as well as
lesser amounts of the normal 311 bp amplicon and larger molecular species. B) Cartoon demonstrating size and sequence of aberrantly spliced
transcripts obtained from transfected HEK293 cells expressing the IVS1 +2T.C CYP17A1 mutation, obtained after TOPO TA subcloning and
sequencing. The asterisks indicate position of in-frame termination codons. C) Cartoon demonstrating splice sites used to generate transcripts
obtained from transfected HEK293 cells expressing the IVS1 +2T.C CYP17A1 mutation. Figure length is not drawn to scale. D) Western blot analysis of
protein obtained from transiently transfected HEK293 cells expressing the wild type (W) and IVS1 +2T.C mutation (Mu) full-length CYP17A1 gene.
Decreased CYP17A1 protein expression was noted for the IVS1 +2T.C mutant full-length CYP17A1 gene compared to the wild-type gene.
doi:10.1371/journal.pone.0025492.g002
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exon-intron boundary, and base pairing to the U1 snRNA 59
terminus occurs in this complex [23]. The pre-mRNA introns can
be divided into U2 and U12 type depending on the spliceosome
being used. The majority of mammalian introns are U2 type and
consist of three subtypes: GT-AG, GC-AG and AT-AC [24].
Previously observation showed that mutation at 59ss position +2
can be tolerated but with decreasing order in splicing efficiency as
+2T . +2C . +2A . +2G [25], [26]. This 59ss +2 site mutation is
intrinsically weak because of a mismatch base pair with U1
snRNA, although the identity of hydrophobicity coefficients of T
and C may compensate for the mismatch at position +2 of GC-AG
introns [27]. These GC-AG splicing sites account for 0.56%–
1.28% of splice donor sites and may exist in one in every 20
alternative mRNA isoforms [28–30].
By using vectors for expressing a CYP17A1 minigene and full
gene, we found the mRNA splicing products are similar, but the
minigene expression vector produced other cryptic mRNAs. This
result may indicate the existence of cis-elements regulating the first
intron splicing in the downstream region of the minigene. The
IVS1 +2T.C mutation utilized the non-canonical GC-AG
splicing donor site, albeit inefficiently, as suggested by the
immunoblot result (Fig 2D). If this GC-AG site was used in vivo,
although low in abundance, then normal CYP17A1 mRNA
transcript and protein would be generated, reducing the severity
of the phenotype. In the patient’s LCL, we detected only CYP17A1
mRNA spanning exons 1-6 derived from the paternal p.R358X
allele, yet we cannot exclude a small fraction of wild-type CYP17A1
transcript using direct sequencing studies. Furthermore, the
patient clinically has severe 17OHD deficiency, with negligible
19-carbon steroid production yet detectable cortisol and partial
breast development. It is difficult to predict how well the non-
canonical GC-AG splicing donor is tolerated in the human gonad
and adrenal gland based on data obtained from heterologous
expression systems or from ectopic CYP17A1 expression in the
LCL. Our data suggest that a trace of wild-type mRNA might be
produced, which indicates that the use of non-canonical splicing
sites in vivo might be under-estimated because of their low
expression level. The determinants of non-canonical GC-AG
splicing donor usage in vivo are unclear, and the loss of trans-acting
factors regulating splicing in the heterologous expression systems
may contribute to these differences. Discrepancies in minigene
experiments, which failed to fully recapitulate the normal mRNA
splicing pattern, was also reported in studies of a splicing site
mutation of the calcium sensing receptor [31].
In summary, we identified a CYP17A1 first intron splicing site
mutation in heterozygous combination with p.R358X leading to
the severe 17OHD. Discrepancies between transient transfection
and LCL experiments were found, highlighting the limitations of
using such model systems for the study of mRNA splicing in the
adrenal and gonad. Based on the clinical and experimental data, it
is likely that the CYP17A1 IVS1 +2T.C severely but not
completely disrupts pre-mRNA splicing. In the analysis of intronic
mutations, a combined use of minigene, full-length gene, LCL,
and native tissues may be necessary to accurately determine the
functional changes caused by the mutation.
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Figure 3. RT and semi-nested PCR analysis of CYP17A1 mRNA from the patient’s LCL. A) Amplicons were derived from RT-PCR spanning
exons 1 and 2 (lane 1, 311 bp band), exons 1 and 3 (lane 2, 644 bp band), or exons 1 and 6 (lane 3, 1191 bp band). The PCR primers used are indicated
at bottom of the figure panel; N.S. indicates a non-specific PCR product. The 1191bp PCR product spans from exon 1 to exon 6, with primer e
designed just 39 to the p.R358X position. B) Direct sequencing (reverse strand) analysis of the 1191bp band showed only the p.R358X mutation
without wild type sequence.
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